Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Petróleo Brasileiro SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Petróleo Brasileiro SA trades at $17.83 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PBR | |
|---|---|---|
Market Cap | $29.60B | $112.19B |
Sector | Health | Technology |
52-Week High | $491.22 | $22.03 |
52-Week Low | $205.48 | $11.54 |
Enterprise Value | $27.56B | $172.61B |
Dividend Yield | — | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Petrobras (PBR) trades at $17.76, down 3.11% today, amid bearish technical signals despite strong Q2 2026 results showing record production and earnings growth. The company maintains robust fundamentals with a P/E of 4.53, ROE of 30.77%, and consistent dividend payments, though cash flow turned negative in 2026. Recent news highlights production exceeding forecasts and strategic expansions in deepwater operations.
PBR presents a value opportunity with attractive valuations and high profitability, but faces headwinds from regulatory uncertainty and volatile oil prices. Analyst consensus is bullish (50% Buy ratings), yet technical indicators suggest near-term pressure. Investors should weigh strong fundamentals against geopolitical and operational risks in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
